Activation/NN
of/IN
NF-kappa/NN
B/NN
by/IN
interleukin/NN
2/CD
in/IN
human/JJ
blood/NN
monocytes/NNS
./.

We/PRP
report/VBP
here/RB
that/IN
interleukin/NN
2/CD
(/(
IL-2/NN
)/)
acts/VBZ
on/IN
human/JJ
blood/NN
monocytes/NNS
by/IN
enhancing/VBG
binding/NN
activity/NN
of/IN
the/DT
transcription/NN
factor/NN
NF-kappa/NN
B/NN
to/TO
its/PRP$
consensus/NN
sequence/NN
in/IN
the/DT
5'/JJ
regulatory/JJ
enhancer/NN
region/NN
of/IN
the/DT
IL-2/NN
receptor/NN
alpha/NN
chain/NN
(/(
p55/NN
)/)
./.
=====
Similarly/RB
,/,
IL-2/NN
activates/VBZ
NF-kappa/NN
B/NN
in/IN
the/DT
human/JJ
monocytic/JJ
cell/NN
line/NN
U/NN
937/CD
,/,
but/CC
not/RB
in/IN
resting/VBG
human/JJ
T-cells/NNS
./.
=====
This/DT
effect/NN
is/VBZ
detectable/JJ
within/IN
15/CD
min/NN
and/CC
peaks/VBZ
1/CD
h/NN
after/IN
exposure/NN
to/TO
IL-2/NN
./.
=====
Enhanced/VBN
NF-kappa/NN
B/NN
binding/NN
activity/NN
is/VBZ
followed/VBN
by/IN
functional/JJ
activation/NN
in/IN
that/IN
inducibility/NN
of/IN
the/DT
IL-2/NN
receptor/NN
alpha/NN
chain/NN
is/VBZ
mediated/VBN
by/IN
enhanced/VBN
NF-kappa/NN
B/NN
binding/NN
and/CC
that/IN
a/DT
heterologous/JJ
promoter/NN
containing/VBG
the/DT
NF-kappa/NN
B/NN
consensus/NN
sequence/NN
(/(
-291/CD
to/TO
-245/CD
)/)
of/IN
the/DT
IL-2/NN
receptor/NN
alpha/NN
chain/NN
gene/NN
is/VBZ
activated/VBN
./.
=====
In/IN
addition/NN
,/,
IL-2/NN
is/VBZ
capable/JJ
of/IN
increasing/VBG
transcript/NN
levels/NNS
of/IN
the/DT
p50/NN
gene/NN
coding/VBG
for/IN
the/DT
p50/NN
subunit/NN
of/IN
the/DT
NF-kappa/NN
B/NN
transcription/NN
factor/NN
,/,
whereas/IN
mRNA/NN
levels/NNS
of/IN
the/DT
p65/NN
NF-kappa/NN
B/NN
gene/NN
remained/VBD
unchanged/JJ
./.